Neuland Laboratories

“As we enter the second half of the year, expectations of growth remain intact for this as well as the following financial year.”

“I think 2027 will grow and then 2028 will also grow, but yes, I do not think we are precise enough to go into more clarity there.”

“I would say yes, it is an inflection year, but 2027-2028 I think it will just be years of good growth”

“We are also planning to inaugurate our new process R&D center at Genome Valley in Hyderabad, which we expect to be fully operational by early next year.”

“I would probably urge investors to look at the investment in Kakinada more from a long-term return perspective rather than something that will give us returns in the immediate timeframe.”

“The Module 2, Module 3, Module 4, which is the peptide investment, will get triggered if Module 1 gets occupied”

“we would still continue with those investments because we believe that there is a sustained demand for peptide API and therefore we will continue that investment”

“So, Kakinada would be slightly long term, so I guess that can be the one that can be deferred a little bit.”

“We have commissioned our new peptide block at Unit One, which has seen encouraging traction and has given us greater confidence and visibility as we plan the next modules of our peptide expansion.”

“the peptide facility, as we mentioned earlier, also has been built keeping in mind a portfolio of projects, and we are fortunate that a couple of those projects are moving forward and we expect this facility to be used by these couple of projects”

“FY2026 was the first year where we actually had greater revenues contributing from CMS in comparison with GDS. We believe the increasing contribution from CMS will remain an important part of Neuland’s evolution over the coming years.”

“So what you have seen in the last three, four quarters is only just the lumpiness associated with commercial shipments”

“Within the commercial molecule, Chirag, this quarter, I think we have recognized revenues probably around from 5 or 6”

“So, at an aggregate level, the business will continue to grow despite some molecules falling off the cliff or rather tapering off the cliff.”

“We expect that the thing will be done probably by Q4 we should be able to start seeing more revenues from the products, which contribute significantly both to the topline as well as the bottomline from those specialty products.”

“One development that has been particularly encouraging is the level of RFP activity that we have seen in this financial year, and it has been the strongest to date.”

“We have made meaningful headway in establishing relationships with big pharma, and we are continuing to make steady progress in this direction.”

“It just seems like it is a combination of China plus one, a combination of maybe favorable funding, India being seen in favorable light.”

“I hardly used to see 100 Crores molecule until five years ago. Today I see numerous 100 Crores molecules. We have even seen 1000 Crores molecules.”

“we found that there are 1000 peptides, synthetic peptides today between IND and commercial that is the number of synthetic peptides that are there. The same number in January 2025 it was only 500”

“Gross margin for the quarter stood at 59.4% compared to 60.1% in Q2 FY2026.”

“EBITDA for the quarter stood at Rs.104.6 Crores, representing a margin of 22.9% compared to Rs.156.9 Crores and a margin of 30.4% during the corresponding period last year.”

“During the first half of the financial year, we also experienced increase in input costs. The geopolitical environment and the ongoing conflicts in different parts of the world have led to volatility in certain raw material prices and escalation in freight and logistics costs.”

“Certainly, there will be certain additions in terms of our headcount to cater one in the regular R&D but also on a longer note there will be additions not only at the R&D center, but also at the manufacturing site for the peptides or other APIs.”

“Our teams continue to work on sourcing strategies, inventory planning, and operational efficiencies to manage these pressures while ensuring continuity of supply to our customers and to the patients.”

“Working capital for the quarter stood at 104 days of sale compared to 84 days in the previous quarter.”

“We have filed 2 DMFs during this period one is Fezolinetant and the other is Ivacaftor, strengthening our GDS portfolio.”

“As individual commercial shipments become larger, a shift in timing can have a greater impact on quarterly revenues”

“As we look at the second half of FY2027, we remain vigilant and are closely watching movements across raw materials, freight, and the wider supply chain.”

“we do not see any expiries happening before 2030 I think that is the way that we look at it.”

“I think in some of those molecules we have had customers have difficulties in terms of them being able to manufacture the product, and that has led to the impact on these products.”

“we do not see a direct threat of AI taking away our work because most of our work is actual work that goes into generating material or designing and demonstrating a process that generates material”

“The total income for the quarter stood at Rs.457.2 Crores compared to Rs.516.1 Crores in the corresponding previous last year.”

“For the H1FY27, the total income stood at Rs.1107.2 Crores compared to Rs.816.7 Crores in H1 FY26.”

“Profit after tax for the quarter was Rs.51.1 Crores compared to Rs.96.5 Crores in Q2 FY2026.”

“EPS for the quarter stood at 39.85 per share.”

“this quarter has been below the trend that we have seen over the last few quarters; however, if we consider the first half of the year it was largely consistent with our expectations.”